<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540694</url>
  </required_header>
  <id_info>
    <org_study_id>NL51598.018.15</org_study_id>
    <nct_id>NCT02540694</nct_id>
  </id_info>
  <brief_title>EBUS vs EUS-B for Diagnosing Sarcoidosis</brief_title>
  <official_title>Endobronchial vs. Esophageal Ultrasound for Diagnosing Sarcoidosis: A Randomized Clinical Trial; - A Standard vs. - ProCore Needle Comparison -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cook Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Endosonography with mediastinal/ hilar nodal sampling is the test of choice to diagnose
      sarcoidosis stage I and II - in case tissue verification of noncaseating granulomas is
      indicated. However, the optimal endosonographic approach (endobronchial or transoesophageal)
      for mediastinal nodal sampling is under discussion.

      Secondly, which needle size or type provides optimal tissue sample quality for granuloma
      detection is unknown. The novel 25 Gauge (G) beveled ProCore needle, allows tissue
      acquisition of small core biopsies in addition to cytological aspirates.

      Hypotheses:

        1. Esophageal ultrasound guided (EUS-B) sampling of intrathoracic lymph nodes has a 14%
           higher granuloma detection rate compared to endobronchial ultrasound (EBUS) guided nodal
           sampling in patients with suspected sarcoidosis stage I/II.

        2. 25G ProCore needles provide superior sample quality compared to conventional 22G needles
           in patients with suspected sarcoidosis stage I/II.

      Study design:

      Investigator initiated, randomized clinical trial. Setting: International, multicenter
      (university and general hospitals)

      Study population:

      Consecutive patients with a clinical and radiologic suspicion of sarcoidosis stage I or II
      and an indication for tissue verification of non-caseating granulomas are eligible for
      inclusion.

      Intervention:

      EBUS vs EUS-B, simultaneously comparing the standard vs novel ProCore needles.

      Main study endpoints:

        1. The granuloma detection rate of endobronchial (EBUS) guided sampling of intrathoracic
           lymph nodes compared to esophageal (EUS-B using the EBUS scope) guided sampling in
           patients with suspected sarcoidosis stage I/II.

        2. Sample quality of conventional 22G vs. 25G ProCore needles in patients with suspected
           sarcoidosis stage I/II.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The granuloma detection rate of endobronchial (EBUS) guided sampling of intrathoracic lymph nodes compared to esophageal (EUS-B using the EBUS scope) guided sampling in patients with suspected sarcoidosis stage I/II.</measure>
    <time_frame>2 weeks after the endosonography procedure.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sample quality of conventional 22G vs. 25G ProCore needles in patients with suspected sarcoidosis stage I/II.</measure>
    <time_frame>9 months after inclusion of last patient.</time_frame>
    <description>The sample quality will be assessed by two independent reference pathologists. The performance of each needle (25 ProCore / standard 22 G) will be scored on five items (the modified Mair score).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Endosonography</condition>
  <arm_group>
    <arm_group_label>EBUS-TBNA using 22G needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EBUS-TBNA using 22G needle (transbronchial route)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBUS-TBNA using 25G ProCore needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EBUS-TBNA using 25G ProCore needle (transbronchial route)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS-B-FNA using 22G needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EUS-B-FNA using 22G needle (transoesophageal route)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS-B-FNA using 25G ProCOre needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EUS-B-FNA using 25G ProCOre needle (transoesophageal route)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endosonography</intervention_name>
    <arm_group_label>EBUS-TBNA using 22G needle</arm_group_label>
    <arm_group_label>EBUS-TBNA using 25G ProCore needle</arm_group_label>
    <arm_group_label>EUS-B-FNA using 22G needle</arm_group_label>
    <arm_group_label>EUS-B-FNA using 25G ProCOre needle</arm_group_label>
    <other_name>EBUS</other_name>
    <other_name>EUS-B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and radiologic suspicion of sarcoidosis stage I (mediastinal or hilar
             lymphadenopathy) or stage II (lymphadenopathy and interparenchymal abnormalities)

          -  Indication for tissue verification of noncaseating granuloma's

          -  Provision of a written informed consent

        Exclusion Criteria:

          -  Life expectancy of less than 6 months

          -  Obvious organ involvement of sarcoidosis with the possibility to confirm granulomas
             with a minimally invasive diagnostic procedure (eg skin lesion or superficial lymph
             node)

          -  Positive acid-fast bacilli sputum test

          -  Contra-indication for endosonography

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jouke T Annema, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence MM Crombag, MD</last_name>
    <phone>31205664356</phone>
    <email>l.m.crombag@amc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jouke T Annema, Prof</last_name>
    <phone>31205664356</phone>
    <email>j.t.annema@amc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence MM Crombag, MD</last_name>
      <phone>31205664356</phone>
      <email>l.m.crombag@amc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jouke T Annema, Prof</last_name>
      <phone>31205664356</phone>
      <email>j.t.annema@amc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>L.M.M. Crombag</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

